Abstract 1610P
Background
In patients with cancer, immunogenicity and efficacy of COVID-19 vaccines is decreased as compared to healthy population. The objective of the study was to evaluate the humoral immunogenicity of COVID-19 vaccines in patients with cancer compared to controls.
Methods
Patients with cancer and controls aged less than 75 years and vaccinated with BNT162b2 or mRNA1273 or Janssen vaccines from the French national multi-center prospective COVID-19 vaccine cohort study (ANRS0001S COV-POPART) were included. Participants with prior history of symptomatic SARS CoV-2 infection, or positive SARS CoV-2 anti-nucleocapsid antibodies were excluded. Percentage (95% confidence interval (CI)) of responders, geometric means (95% CI) of anti-Spike SARS-CoV-2 IgG antibodies (ELISA) and specific neutralizing antibodies against ancestral strain were estimated one month after the second vaccine dose.
Results
We included 1,196 participants (171 patients with cancer and 1,025 controls). Patients with cancer were older than controls: 61.2 years (52.1 – 67.8) vs 47.8 years (37.1 – 57.5) and more frequently female (65.5% vs 50.4%). The most frequent cancers were breast (58, 35.2%) and lung cancer (37, 22.7%), 80 (48.8%) were metastatic, 145 (88.4%) had received no treatment since less than 6 months, 25 (18.2%) on immunotherapy. Participants were mostly vaccinated with BNT162b2 (83.1% and 84.6%, respectively in patients with cancer and controls). Proportions of patients with cancer were lower to develop anti-Spike IgG (93.0 [88.1; 96.3]) vs 100.0 [99.6; 100.0) and neutralizing antibodies (86.4 [80.3; 91.2] vs 99.7 [99.1; 99.9]). Patients with cancer had lower levels of anti-Spike antibodies (877.1 [727.4; 1057.6] vs 1415.8 [1345.2; 1490.1] BAU/mL,) and of seroneutralization titers (126.8 [100.7; 159.7] vs 316.0 [294.9; 338.5] titers) than controls. Multivariable analysis on non-responders and effect of a third dose will be presented.
Conclusions
Patients with cancer had good response rates one month after two doses of COVID-19 vaccines. Nonetheless, seroneutralization titers were lower than in the control group.
Clinical trial identification
NCT04824651.
Editorial acknowledgement
Legal entity responsible for the study
Agence Nationale de Recherche sur le SIDA, les hépatites virales et maladies infectieuses émergentes, Paris, France.
Funding
Agence National de Recherche sur le SIDA, les hépatites virales et maladies infectieuses émergentes, Ministère des Solidarités et de la Santé, Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation.
Disclosure
L.B. Luong Nguyen: Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Institutional, Principal Investigator: Pfizer. P. Loubet: Financial Interests, Personal, Advisory Role: AstraZeneca, GlaxoSmithKline, Janssen, Sanofi Pasteur; Non-Financial Interests, Personal, Invited Speaker: Pfizer, Sanofi Pasteur. N. Dohollou: Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Genomic Health, MSD, Novartis, Pfizer; Financial Interests, Personal, Advisory Role, And Speaker: Daiichi; Financial Interests, Personal and Institutional, Advisory Role, Speaker and research grant: Lilly; Financial Interests, Personal, Advisory Role, Speaker and research grant: Roche; Financial Interests, Personal, Advisory Role, Speaker: Seagen. O. Tredan: Financial Interests, Personal, Advisory Role: Roche, MSD, Novartis, Pfizer, AstraZeneca, Daiichi, Eisai, Pierre Fabre, Seagen, Gilead; Financial Interests, Institutional, Research Grant: Roche, MSD, BMS. Z. Maakaroun-Vermesse: Non-Financial Interests, Personal, Funding, attendance to conference: GSK; Non-Financial Interests, Personal, Funding, Attendance to conference: Sanofi; Non-Financial Interests, Personal, Funding, Invitation to conference: Pfizer. E. Fourn: Financial Interests, Personal, Invited Speaker: MSD. O. Launay: Financial Interests, Institutional, Principal Investigator: GSK, MSD, Pfizer, AstraZeneca, Sanofi; Financial Interests, Personal, Invited Speaker: GSK, Sanofi, MSD, Pfizer, AstraZeneca; Financial Interests, Personal, Advisory Board: MSD, Sanofi. J. Blay: Financial Interests, Personal, Advisory Board: Bayer, Deciphera, GSK, Roche; Financial Interests, Personal, Invited Speaker: Pharmamar; Financial Interests, Institutional, Invited Speaker: MSD, MSD; Financial Interests, Personal, Member of the supervisory board: Innate pharma; Financial Interests, Institutional, Funding: MSD, BMS, Deciphera; Financial Interests, Institutional, Research Grant: Astra Zeneca, Roche, Bayer, GSK, Novartis, OSE pharma. J. Spano: Financial Interests, Personal, Advisory Role, Speaker: Roche, MSD; Financial Interests, Personal, Advisory Role: Biogaran; Financial Interests, Personal, Invited Speaker: AstraZeneca, Leopharma, Mylan, Pfizer, BMS, Novartis, PFO, myriads, Gilead, Lilly. All other authors have declared no conflicts of interest.